ClinicalTrials.gg
RecruitingNCT06843122FOOTCELLUpdated Oct 26, 2026

Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot Syndrome.

A Phase 2 interventional study of Allogeneic ADSC/ASC (alloADSC-DFU-RL) and Placebo (PL-DFU-RL) in Diabetic Foot Ulcer, sponsored by Medical University of Warsaw. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Medical University of Warsaw · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 26, 2026Now RecruitingFirst site in Poland+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Diabetic Foot with a site in Poland — 3 open to participants now, 3 under way, 1 of them phase 3. Diabetic Foot · Poland.

Planned enrollment
12th of 19
105 · median 159
Started
2025
the only one that year
Phase 2
2 of 20
1 open now
Registered
19th of 20
by date
Lead sponsor
2 of 20
Medical University of Warsaw

Among the 20 studies in Diabetic Foot with a site in Poland, this one is the 12th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 2, and was the 19th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

3 of the 20 studies in Diabetic Foot with a site in Poland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Diabetic Foot with a site in Poland, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the safety and efficacy of an advanced therapy medicinal product containing live allogeneic adipose-derived mesenchymal stem cells (ADSC/ASC) for the treatment of diabetic foot ulcers in a randomized, double-blind, three-arm study.

Read the detailed description

Patients will be randomized and assigned to one of three study groups and will receive the following study treatments: 1) two doses of cell solution; 2) one dose of cell solution and one dose of placebo solution; or 3) two doses of placebo solution. During the study, patients will attend weekly visits for routine monitoring and standard-of-care (SOC) treatment. The IMP or placebo will be administered two weeks apart, on days 0 and 14. Control visits are scheduled on days 7, 21, 28, 35, and 42, for a total of seven visits during the active phase of the study. Follow-up visits will be conducted 8, 26, and 52 weeks after the last visit of the active phase (day 42).

03

Conditions studied

  • Diabetic Foot Ulcer

Keywords

  • adipose-derived mesenchymal stem cells
  • chronic wounds
  • diabetes
  • foot ulcer
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years at the time of consent
  2. The patient's psychophysical and legal ability to give to participate in the study,
  3. Signing the informed consent document for participation in the study,
  4. A confirmed diagnosis of type 1 diabetes, type 2 diabetes, LADA, MODY, or other types of diabetes, documented in accordance with current diagnostic criteria.
  5. Ulcer classified as diabetic foot syndrome (DFS) of neuropathic and/or neuroischemic etiology corresponding to grade IA/IIA and IC/IIC according to the University of Texas classification (Appendix E),
  6. A period of not less than 6 weeks since the onset of the ulceration,
  7. Presence of a wound of 1-25 cm2 (after wound debridement),
  8. Satisfactory blood supply to the wound area (assessed by transcutaneous measurement of oxygen partial pressure, if not less than 30 mmHg, or measurement of systolic arterial pressure on the posterior tibial and/or dorsal artery of the foot, which will not be less than 50 mmHg) to exclude patients who require revascularisation therapy
  9. A value (HbA1c) of no more than 11%,
  10. General health status of the patient that, in the opinion of the investigator, allows participation in all study procedures,
  11. Use of a form of wound relief recommended by the Investigator,
  12. In the case of women of , agreement to use of methods of effective to avoid pregnancy and/or based on the following criteria: - a woman who is incapable of having offspring (after hysterectomy or bilateral ovarian resection or after menopause, defined as a period of at least 12 months since the last menstrual period) is exempt from pregnancy testing - a woman capable of having offspring with a negative pregnancy test result prior to the first day dose of the study product and who agrees to cycle pregnancy tests according to the study protocol and to use appropriate contraception until one month after the end of the active phase of the study (up to V6), or 2 months after the last administration of the study drug. For men - fertile men who are sexually active with a partner who may become pregnant are required to use a barrier method throughout the entire duration of the study, and the partners of study participants (who are capable of bearing children) are required to use the same contraceptive methods as female study participants until Visit V6.

Exclusion criteria

Exclusion Criteria:

  1. Etiology of the ulcer other than diabetic foot syndrome,
  2. Presence of active infection in the wound at the time of inclusion in the study,
  3. Wound area \<1 cm² or >25 cm²,
  4. Patient was eligible to participate in another clinical trial in the 4 weeks preceding study eligibility.
  5. limb ischaemia (assessed by transcutaneous measurement of oxygen partial pressure if less than 30 mmHg or measurement of systolic arterial pressure on the posterior tibial and dorsal artery of the foot which is less than 50 mmHg)
  6. Presence of an active phase of Charcot joint,
  7. Osteitis and/or osteomyelitis, including cases assessed using a positive probe-to-bone test,
  8. Revascularisation procedure in the affected lower limb within less than 3 months prior to study inclusion or planned revascularisation procedure,
  9. Chronic kidney disease with \< 20 ml/min,
  10. Pregnancy and lactation,
  11. Allergy to thrombin,
  12. Active venous thrombosis,
  13. Systemic diseases in the exacerbation stage (acute or decompensated), including heart, kidney, and liver diseases,
  14. Active alcoholic disease or psychoactive drug addiction,
  15. Allergies to dressing materials used in the study,
  16. Oral/intravenous antibiotic therapy at the time of inclusion in the study,
  17. A patient undergoing therapy, including systemic therapy (within 30 days prior to study inclusion). Topical corticosteroid therapy does not constitute an exclusion criterion.
  18. Patients undergoing immunotherapy for allergic diseases (within 30 days prior to the screening visit -calculated from the last dose of such therapy) or those planning to initiate or resume such therapy during the clinical trial,
  19. Active cancerous process or cancer in the last 5 years, excluding locally malignant tumors that do not involve the tissues of the foot
  20. Presence of a clinically known active, uncontrolled infection, e.g., , , , and venereal disease (syphilis),
  21. Significant features of malnutrition further impairing the healing process, regardless of the cause (albumin \< 2.5 g/dL and total protein \< 5g/dL),
  22. concentration \< 9g/dL,
  23. Serum transaminase activity (alanine and aspartate) exceeding 3x the (local) .
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    A - Two administrations of allogeneic ADSC/ASC

    Participants will receive two administrations of allogeneic ADSC/ASC, at V0 (Day 0) and V2 (Day 14), in addition to standard-of-care (SOC) treatment for diabetic foot ulcer.

    Biological: Allogeneic ADSC/ASC (alloADSC-DFU-RL)

  • Experimental
    B - One administration of allogeneic ADSC/ASC and one administration of placebo

    Participants will receive allogeneic ADSC/ASC at V0 (Day 0), followed by placebo at V2 (Day 14), in addition to standard-of-care (SOC) treatment for diabetic foot ulcer.

    Biological: Allogeneic ADSC/ASC (alloADSC-DFU-RL) · Biological: Placebo (PL-DFU-RL)

  • Placebo comparator
    C - Two administrations of placebo

    Participants will receive two administrations of placebo, at V0 (Day 0) and V2 (Day 14), in addition to standard-of-care (SOC) treatment for diabetic foot ulcer.

    Biological: Placebo (PL-DFU-RL)

Interventions

  • BiologicalAllogeneic ADSC/ASC (alloADSC-DFU-RL)

    Allogeneic ADSC/ASC suspended in Ringer's lactate and reconstructed with fibrin sealant for application to the wound surface.

  • BiologicalPlacebo (PL-DFU-RL)

    Ringer's lactate without ADSC/ASC, reconstructed with fibrin sealant for application to the wound surface.

06

What researchers measure

Primary outcomes

  1. Change in wound size (%) at 6 weeks after first study treatment administration compared to baseline with the actual wound size measured by the independent assessor.

    Percentage change in wound size, measured by an independent assessor using a standardized wound area measurement method. The calculation is based on the difference between the baseline wound size and the wound size at 6 weeks, expressed as a percentage of the baseline value.

    Time frame: 6 weeks after the first administration

  2. Type, frequency and severity of adverse events (assessed according CTCAE v5.0); change from baseline of laboratory parameters and selected vital signs of the participants.

    Adverse events will be assessed based on type, frequency, and severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Changes from baseline in laboratory parameters and selected vital signs will be evaluated using standardized clinical measurement methods.

    Time frame: 6 weeks after the first administration

Secondary outcomes

  1. Early efficacy of the allogenic ADSC/ASC defined as percentage of patients with significant clinical success defined as complete wound closure (100% epithelialization), or partial epithelialization of the wound (>50% epithelialization)

    The percentage of patients achieving significant clinical success, defined as either complete wound closure (100% epithelialization) or partial epithelialization of the wound (\>50%). Wound epithelialization will be assessed using standardized wound assessment criteria by an independent assessor.

    Time frame: 6 weeks after the first administration

  2. Long-term efficacy of the allogenic ADSC/ASC defined as percentage of patients with significant clinical success defined as complete wound closure (100% epithelialization), or partial epithelialization of the wound (>50% epithelialization) over time.

    The percentage of patients achieving significant clinical success, defined as either complete wound closure (100% epithelialization) or partial epithelialization of the wound (\>50%), assessed over time. Wound epithelialization will be evaluated using standardized wound assessment criteria by an independent assessor at predefined time points.

    Time frame: Through study completion, an average of 1 year

  3. The dynamics of wound healing defined as the time required for patients to reach the wound size reduction thresholds: 50% reduction of the wound; maximum reduction of the wound area (%); complete wound healing .

    The time required for patients to achieve predefined wound size reduction thresholds, including 50% wound size reduction, maximum wound area reduction (percentage), and complete wound healing (100% epithelialization). Wound size will be measured using standardized wound assessment methods by an independent assessor at predefined time points.

    Time frame: 6 weeks after the first administration and through study completion, an average of 1 year

  4. Absolute change in the wound-associated pain perception over time assessed by the patient using visual analogue scale.

    Evaluation of the wound-associated pain, assessed by the patient using visual analogue scale. The minimum value is 0 and means "no pain" and the maximum value is 10 and means "the worst possible pain". The lower value the better outcome.

    Time frame: 6 weeks after the first administration and through study completion, an average of 1 year

  5. Additional safety parameters such as wound infection requiring antibiotic treatment expressed as total number of patients, and number of antibiotic therapies per patient.

    The total number of patients with wound infections requiring antibiotic treatment and the number of antibiotic therapy courses per patient. Infections will be assessed based on clinical criteria and standard medical guidelines.

    Time frame: 6 weeks after the first administration and through study completion, an average of 1 year .

  6. Changes in quality of life parameters assessed by the dedicated QoL questionnaire.

    Evaluation of the patient's quality of life, assessed by the dedicated QoL questionnaire. The QoL questionnaire consists of 10 questions. Each question is scored 1 to 5. The minimum score is 10 and it means "the best possible state of health", and the maximum score is 50, which means ,,the worst possible state of health".

    Time frame: 6 weeks after the first administration and through study completion, an average of 1 year

Other outcomes

  1. Evaluation of the additional safety and efficacy parameters such as the percentage of patients requiring lower or upper limb amputation or the percentage of patients experiencing CVD events (CVD death, hospitalization for CVD reason)

    The percentage of patients requiring lower or upper limb amputation and the percentage of patients experiencing cardiovascular events (CVD death, hospitalization for CVD reasons). Events will be assessed based on clinical diagnosis and medical records.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Szpital Bielanski Im.Ks.Jerzego Popieluszki Samodzielny Publiczny Zaklad Opieki Zdrowotnej
    Warsaw, 01-809, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Feb 2027, 23 months after the start.

Of 31 phase 2 interventional studies under Diabetic Foot, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2024
First posted
Feb 24, 2025
StartActual
Mar 5, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Aug 1, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
1 site added — first site in Poland
Show site
  • Szpital Bielanski Im.Ks.Jerzego Popieluszki Samodzielny Publiczny Zaklad Opieki Zdrowotnej · Warsaw, Poland
Oct 26, 2026
Start date
Mar 8, 2025→Mar 5, 2025 (actual)
Oct 26, 2026
Eligibility
7 inclusion criteria edited, 2 added, 5 removed; 11 exclusion criteria edited, 2 added, 3 removed
What changed in the criteria
Inclusion criteria
  • EditedAge >≥ 18 years at the time of consent,
  • AddedA confirmed diagnosis of type 1 diabetes, type 2 diabetes, LADA, MODY, or other types of diabetes, documented in accordance with current diagnostic criteria.
  • EditedDurationA period of the ulcer not less than 6 weeks since the onset of the ulceration,
  • EditedPresence of a wound with an area of 1-25 cm²cm2 (after wound debridement),
  • RemovedSatisfactory blood supply to the wound area:
  • Removedassessed using transcutaneous oxygen pressure measurement, if its value is not less than 30 mmHg,
  • EditedSatisfactory blood supply to the wound area (assessed by transcutaneous measurement of oxygen partial pressure, if not less than 30 mmHg, or measurement of systolic bloodarterial pressure aton the posterior tibial artery and/or dorsalis pedisdorsal artery of the foot, which iswill not be less than 50 mmHg,) to exclude patients who require revascularizationrevascularisation therapy,
  • EditedGlycated hemoglobinA glycated haemoglobin value (HbA1c) <of no more than 11%,
  • EditedGeneral health status of the patient that, which in the opinion of the investigator's opinion, allows participation in all study procedures,
  • EditedUse of thea form of wound offloading methodrelief recommended by the investigatorInvestigator,
  • RemovedUse of effective contraception methods to avoid pregnancy (see also Appendix F) and/or based on the following criteria:
  • Removeda woman who is unable to have children (after a hysterectomy or bilateral oophorectomy or post-menopause, defined as a period of at least 12 months since the last menstrual period) is exempt from pregnancy tests,
  • Removeda woman able to have children with a negative pregnancy test result before the administration of the investigational product on the first day and who agrees to periodic pregnancy testing according to the study protocol and to use highly effective contraceptive methods for one month after the end of the active phase of the study (from V6), or two months after the last administration of the investigational drug (from V2).
  • AddedIn the case of women of childbearing potential, agreement to use of methods of effective contraception to avoid pregnancy and/or based on the following criteria: - a woman who is incapable of having offspring (after hysterectomy or bilateral ovarian resection or after menopause, defined as a period of at least 12 months since the last menstrual period) is exempt from pregnancy testing - a woman capable of having offspring with a negative pregnancy test result prior to the first day dose of the study product and who agrees to cycle pregnancy tests according to the study protocol and to use appropriate contraception until one month after the end of the active phase of the study (up to V6), or 2 months after the last administration of the study drug. For men - fertile men who are sexually active with a partner who may become pregnant are required to use a barrier method throughout the entire duration of the study, and the partners of study participants (who are capable of bearing children) are required to use the same contraceptive methods as female study participants until Visit V6.
Exclusion criteria
  • EditedPresence of an active infection in the wound at the time of inclusion in the study,
  • EditedThe patientPatient was enrolledeligible to participate in another clinical trial withinin the 4 weeks preceding the qualification for this studystudy eligibility.
  • RemovedClinically significant limb ischemia:
  • Removedassessed using transcutaneous oxygen pressure measurement, if its value is lower than 30 mmHg
  • Removedor measurement of systolic blood pressure at the posterior tibial artery and/or dorsalis pedis artery, if it is lower than 50 mmHg,
  • AddedClinically significant limb ischaemia (assessed by transcutaneous measurement of oxygen partial pressure if less than 30 mmHg or measurement of systolic arterial pressure on the posterior tibial and dorsal artery of the foot which is less than 50 mmHg)
  • ChangedBefore Suspected osteitis and/or osteomyelitis within the study wound,Now Osteitis and/or osteomyelitis, including cases assessed using a positive probe-to-bone test,
  • EditedRevascularizationRevascularisation procedure onin the affected lower limb within less than 3 months prior to study inclusion or planned revascularizationrevascularisation procedure,
  • EditedActive alcoholalcoholic disease or addiction to psychoactive substancesdrug addiction,
  • EditedPatientA patient undergoing immunosuppressive therapy, including systemic corticosteroid therapy (within 30 days prior to study inclusion),. Topical corticosteroid therapy does not constitute an exclusion criterion.
  • AddedPatients undergoing immunotherapy for allergic diseases (within 30 days prior to the screening visit -calculated from the last dose of such therapy) or those planning to initiate or resume such therapy during the clinical trial,
  • EditedActive cancercancerous process or cancer disease in the last 5 years, excluding locally malignant cancerstumors that do not involvinginvolve the tissues of the foot tissues,
  • EditedPresence of knowna clinically known active, uncontrolled infections such as hepatitisinfection, e.g., Hepatitis B, hepatitisHepatitis C, HIV, and venereal disease (syphilis),
  • EditedSignificant features of malnutrition additionallyfurther impairing the healing process, regardless of the cause (albumin < 2.5 g/dldL and total protein < 5 g5g/dldL),
  • EditedHemoglobin levelsconcentration < 9 g9g/dldL,
  • EditedSerum transaminase activity (alanine and aspartate) activity higherexceeding 3x the upper limit of normal (locallylocal) .
Oct 26, 2026
Interventions
Added Biological: Allogeneic ADSC/ASC (alloADSC-DFU-RL)·Biological: Placebo (PL-DFU-RL); removed Biological: A - Allogenic ADSC cells in fibrin solution - two times administration ADSC/ASC·Biological: B - Allogenic ADSC cells in fibrin solution - one time administration of ADSC/ASC, one time of placebo·C - Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.. Arm changed B - ADSC/ASC cells in fibrin solution - one administration of ADSC/ASC, one administration placebo→B - One administration of allogeneic ADSC/ASC and one administration of placebo. Arms added: A - Two administrations of allogeneic ADSC/ASC·C - Two administrations of placebo; arms removed: A - ADSC/ASC cells in fibrin solution - two times administration of ADSC/ASC·C - Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.
Oct 26, 2026
Title
Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL)Syndrome.
Oct 26, 2026
Sponsor
Collaborators added: University of Lodz
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Poland
    Show site
    • Szpital Bielanski Im.Ks.Jerzego Popieluszki Samodzielny Publiczny Zaklad Opieki Zdrowotnej · Warsaw, Poland
    Start date Mar 8, 2025→Mar 5, 2025 (now actual)
    Eligibility 7 inclusion criteria edited, 2 added, 5 removed; 11 exclusion criteria edited, 2 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • EditedAge >≥ 18 years at the time of consent,
    • AddedA confirmed diagnosis of type 1 diabetes, type 2 diabetes, LADA, MODY, or other types of diabetes, documented in accordance with current diagnostic criteria.
    • EditedDurationA period of the ulcer not less than 6 weeks since the onset of the ulceration,
    • EditedPresence of a wound with an area of 1-25 cm²cm2 (after wound debridement),
    • RemovedSatisfactory blood supply to the wound area:
    • Removedassessed using transcutaneous oxygen pressure measurement, if its value is not less than 30 mmHg,
    • EditedSatisfactory blood supply to the wound area (assessed by transcutaneous measurement of oxygen partial pressure, if not less than 30 mmHg, or measurement of systolic bloodarterial pressure aton the posterior tibial artery and/or dorsalis pedisdorsal artery of the foot, which iswill not be less than 50 mmHg,) to exclude patients who require revascularizationrevascularisation therapy,
    • EditedGlycated hemoglobinA glycated haemoglobin value (HbA1c) <of no more than 11%,
    • EditedGeneral health status of the patient that, which in the opinion of the investigator's opinion, allows participation in all study procedures,
    • EditedUse of thea form of wound offloading methodrelief recommended by the investigatorInvestigator,
    • RemovedUse of effective contraception methods to avoid pregnancy (see also Appendix F) and/or based on the following criteria:
    • Removeda woman who is unable to have children (after a hysterectomy or bilateral oophorectomy or post-menopause, defined as a period of at least 12 months since the last menstrual period) is exempt from pregnancy tests,
    • Removeda woman able to have children with a negative pregnancy test result before the administration of the investigational product on the first day and who agrees to periodic pregnancy testing according to the study protocol and to use highly effective contraceptive methods for one month after the end of the active phase of the study (from V6), or two months after the last administration of the investigational drug (from V2).
    • AddedIn the case of women of childbearing potential, agreement to use of methods of effective contraception to avoid pregnancy and/or based on the following criteria: - a woman who is incapable of having offspring (after hysterectomy or bilateral ovarian resection or after menopause, defined as a period of at least 12 months since the last menstrual period) is exempt from pregnancy testing - a woman capable of having offspring with a negative pregnancy test result prior to the first day dose of the study product and who agrees to cycle pregnancy tests according to the study protocol and to use appropriate contraception until one month after the end of the active phase of the study (up to V6), or 2 months after the last administration of the study drug. For men - fertile men who are sexually active with a partner who may become pregnant are required to use a barrier method throughout the entire duration of the study, and the partners of study participants (who are capable of bearing children) are required to use the same contraceptive methods as female study participants until Visit V6.
    Exclusion criteria
    • EditedPresence of an active infection in the wound at the time of inclusion in the study,
    • EditedThe patientPatient was enrolledeligible to participate in another clinical trial withinin the 4 weeks preceding the qualification for this studystudy eligibility.
    • RemovedClinically significant limb ischemia:
    • Removedassessed using transcutaneous oxygen pressure measurement, if its value is lower than 30 mmHg
    • Removedor measurement of systolic blood pressure at the posterior tibial artery and/or dorsalis pedis artery, if it is lower than 50 mmHg,
    • AddedClinically significant limb ischaemia (assessed by transcutaneous measurement of oxygen partial pressure if less than 30 mmHg or measurement of systolic arterial pressure on the posterior tibial and dorsal artery of the foot which is less than 50 mmHg)
    • ChangedBefore Suspected osteitis and/or osteomyelitis within the study wound,Now Osteitis and/or osteomyelitis, including cases assessed using a positive probe-to-bone test,
    • EditedRevascularizationRevascularisation procedure onin the affected lower limb within less than 3 months prior to study inclusion or planned revascularizationrevascularisation procedure,
    • EditedActive alcoholalcoholic disease or addiction to psychoactive substancesdrug addiction,
    • EditedPatientA patient undergoing immunosuppressive therapy, including systemic corticosteroid therapy (within 30 days prior to study inclusion),. Topical corticosteroid therapy does not constitute an exclusion criterion.
    • AddedPatients undergoing immunotherapy for allergic diseases (within 30 days prior to the screening visit -calculated from the last dose of such therapy) or those planning to initiate or resume such therapy during the clinical trial,
    • EditedActive cancercancerous process or cancer disease in the last 5 years, excluding locally malignant cancerstumors that do not involvinginvolve the tissues of the foot tissues,
    • EditedPresence of knowna clinically known active, uncontrolled infections such as hepatitisinfection, e.g., Hepatitis B, hepatitisHepatitis C, HIV, and venereal disease (syphilis),
    • EditedSignificant features of malnutrition additionallyfurther impairing the healing process, regardless of the cause (albumin < 2.5 g/dldL and total protein < 5 g5g/dldL),
    • EditedHemoglobin levelsconcentration < 9 g9g/dldL,
    • EditedSerum transaminase activity (alanine and aspartate) activity higherexceeding 3x the upper limit of normal (locallylocal) .
    Interventions Added Biological: Allogeneic ADSC/ASC (alloADSC-DFU-RL)·Biological: Placebo (PL-DFU-RL); removed Biological: A - Allogenic ADSC cells in fibrin solution - two times administration ADSC/ASC·Biological: B - Allogenic ADSC cells in fibrin solution - one time administration of ADSC/ASC, one time of placebo·C - Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.. Arm changed B - ADSC/ASC cells in fibrin solution - one administration of ADSC/ASC, one administration placebo→B - One administration of allogeneic ADSC/ASC and one administration of placebo. Arms added: A - Two administrations of allogeneic ADSC/ASC·C - Two administrations of placebo; arms removed: A - ADSC/ASC cells in fibrin solution - two times administration of ADSC/ASC·C - Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.
    Sponsor Collaborators added: University of Lodz
    Title Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL)Syndrome.
    + 5 other changes: index terms, verification date, oversight details, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06843122
Collaborators
Medical Research Agency, Poland, University of Lodz
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Mar 5, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Beata Mrozikiewicz-Rakowska, Assoc.Prof.
Contact
klinendo@bielanski.med.pl
+48 225690529
Beata Mrozikiewicz-Rakowska, Assoc.Prof.
principal investigator · Bielanski Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion